This page in Swedish

Martin Gunnarsson

Title: Affiliated Researcher School/office: School of Medical Sciences

Email:

Phone: +46 19 303000

Room: -

Martin Gunnarsson
Research subject

About Martin Gunnarsson

Martin Gunnarsson is associate professor of neurology at Örebro University and consultant at Örebro University Hospital.

Martin Gunnarsson trained at Umeå University and obtained his PhD in immunology with his thesis The conformational complexity of alpha2-macroglobulin and its relation to multiple sclerosis. He received his Degree of Master of Science in Medicine in 2002, his medical license in 2004 and completed his specialist medical training in neurology in 2009.

Research

Martin Gunnarsson’s research is focused mainly on neuroinflammation and various aspects of the disease multiple sclerosis (MS). After previously contributing mainly to experimental research, his projects in recent years have been of a clinical or translational nature. His research has revolved around risk factors, disease mechanisms and monitoring of disease activity in MS, among other things. Projects have also included clinical treatment research, and he has served as a clinical investigator in several clinical trials, both randomised and observational. Studying the progression of MS with different biomarkers and radiological techniques has been of particular interest. He has collaborated in the MS field both nationally and internationally.

Teaching

In 2011–2016, Martin Gunnarsson was responsible for building up the neuroscience curriculum within the Programme in Medicine at Örebro University. He has had various teaching assignments in both the Programme in Medicine and other professional healthcare programmes and has served as an examiner, and supervises PhD students. Martin has also lectured in and organised various continuing professional development courses, conferences and symposia on health and medical care and served as chair of the national neurology meeting in 2016.

Collaborations and assignments

Martin Gunnarsson is head of the School of Medical Sciences at Örebro University and was previously head of Department of neurology and rehabilitation medicine at Örebro University Hospital. He has chaired the Swedish Neurological Society and been a member of the national council on nervous system diseases. Martin is a board member of medical research foundation Nyckelfonden.

 

Publications

Articles in journals |  Articles, reviews/surveys |  Conference papers | 

Articles in journals

Ekström, E. , Rosengren, V. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2021). A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3). Multiple Sclerosis, 27 (Suppl. 2), 616-617.
Rosengren, V. , Ekström, E. , Forsberg, L. , Kågström, S. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2021). Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10). Multiple Sclerosis, 27 (Suppl. 2), 623-624.
Rosengren, V. , Ekström, E. , Forsberg, L. , Kågström, S. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. & et al. (2021). Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 5" (IMSE 5). Multiple Sclerosis, 27 (Suppl. 2), 615-616.
Rosengren, V. , Ekström, E. , Forsberg, L. , Kågström, S. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2021). Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4). Multiple Sclerosis, 27 (Suppl. 2), 612-613.
Grut, V. , Biström, M. , Salzer, J. , Stridh, P. , Jons, D. , Gustafsson, R. , Fogdell-Hahn, A. , Huang, J. & et al. (2021). Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis: a presymptomatic case-control study. European Journal of Neurology, 28 (9), 3072-3079.
Alping, P. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. , Lycke, J. & et al. (2021). Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab. Multiple Sclerosis, 27 (Suppl. 2), 21-22.
Biström, M. , Jons, D. , Engdahl, E. , Gustafsson, R. , Huang, J. , Brenner, N. , Butt, J. , Alonso-Magdalena, L. & et al. (2021). Epstein-Barr virus infection after adolescence and Human herpesvirus 6A as risk factors for multiple sclerosis. European Journal of Neurology, 28 (2), 579-586.
Biström, M. , Hultdin, J. , Andersen, O. , Alonso-Magdalena, L. , Jons, D. , Gunnarsson, M. , Vrethem, M. & Sundström, P. (2021). Leptin levels are associated with multiple sclerosis risk. Multiple Sclerosis, 27 (1), 19-27.
Petersson, M. , Feresiadou, A. , Jons, D. , Ilinca, A. , Lundin, F. , Johansson, R. , Budzianowska, A. , Roos, A. & et al. (2021). Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study. Neurology, 97 (14), E1382-E1391.
Westerdahl, E. , Gunnarsson, M. , Wittrin, A. & Nilsagård, Y. (2021). Pulmonary Function and Respiratory Muscle Strength in Patients with Multiple Sclerosis. Multiple Sclerosis International, 2021.
Ekström, E. , Rosengren, V. , Kågström, S. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. & et al. (2021). Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile. Multiple Sclerosis, 27 (Suppl. 2), 626-627.
Ekström, E. , Rosengren, V. , Kågström, S. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. & et al. (2021). The long-term safety and effectiveness of natalizumab (IMSE 1) - Real-world data from a Swedish nationwide pharmaco-epidemiological study. Multiple Sclerosis, 27 (Suppl. 2), 618-619.
Longinetti, E. , Englund, S. , Burman, J. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. , Lycke, J. & et al. (2021). Trajectories of processing speed, disability, and their connections, over the years following disease modulatory treatment initiation among relapsing-remitting multiple sclerosis patients. Multiple Sclerosis, 27 (Suppl. 2), 677-678.
Forsberg, L. , Kågström, S. , Leandersson, Å. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2020). A swedish post-market surveillance study: long-term effectiveness and safety of cladribine tablets (IMSE 10) for patients treated at least 12 months. Multiple Sclerosis, 26 (3 Suppl.), 254-254.
Forsberg, L. , Kågström, S. , Leandersson, Å. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2020). A swedish post-market surveillance study: long-term effectiveness and safety of dimethyl fumarate (imse 5) for patients treated at least 36 months: on-demand eposters p0001-p0286. Multiple Sclerosis, 26 (3 Suppl.), 254-255.
Leandersson, Å. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2020). A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (imse 3) for patients treated for at least 36 months. Multiple Sclerosis, 26 (3 Suppl.), 252-253.
Forsberg, L. , Kågström, S. , Leandersson, Å. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2020). A swedish post-market surveillance study of the long-term effectiveness and safety of teriflunomid (IMSE 4) for patients treated at least 36 months. Multiple Sclerosis, 26 (3 Suppl.), 253-254.
Alping, P. , Askling, J. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. & et al. (2020). Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 87 (5), 688-699.
Granqvist, M. , Burman, J. , Gunnarsson, M. , Lycke, J. , Nilsson, P. , Olsson, T. , Sundström, P. , Svenningsson, A. & et al. (2020). Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. Multiple Sclerosis, 26 (12), 1532-1539.
Kågström, S. , Leandersson, Å. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2020). Efficacy and safety in patients treated with natalizumab for at least 10 years - real-world data from a swedish national surveillance study (IMSE 1). Multiple Sclerosis, 26 (3 Suppl.), 279-280.
Luna, G. , Alping, P. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. , Hillert, J. , Langer-Gould, A. & et al. (2020). Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology, 77 (2), 184-191.
Kågström, S. , Leandersson, Å. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2020). Real-world data of peginterferon beta-1a from a swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile. Multiple Sclerosis, 26 (3 Suppl.), 302-302.
Leandersson, Å. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2020). Relation of edss to patient-reported outcome measurements in ms: real-world data from a swedish nationwide study of fingolimod (imse 2). Multiple Sclerosis, 26 (3 Suppl.), 187-188.
Forsberg, L. , Kågström, S. , Fält, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2019). A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4). Multiple Sclerosis, 25 (Suppl. 2), 316-316.
Fält, A. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2019). A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months. Multiple Sclerosis, 25 (Suppl. 2), 327-328.
Fält, A. , Kågström, S. , Forsberg, L. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2019). A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months. Multiple Sclerosis, 25 (Suppl. 2), 536-537.
Forsberg, L. , Kågström, S. , Fält, A. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2019). Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5). Multiple Sclerosis, 25 (Suppl. 2), 316-317.
de Flon, P. , Laurell, K. , Sundström, P. , Blennow, K. , Söderström, L. , Zetterberg, H. , Gunnarsson, M. & Svenningsson, A. (2019). Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurologica Scandinavica, 139 (5), 462-468.
Kågström, S. , Fält, A. , Forsberg, L. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2019). Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1). Multiple Sclerosis, 25 (Suppl. 2), 763-764.
Biström, M. , Hultdin, J. , Andersen, O. , Alonso-Magdalena, L. , Jons, D. , Gunnarsson, M. , Vrethem, M. & Sundström, P. (2019). Leptin levels are associated with multiple sclerosis risk. Multiple Sclerosis, 25 (Suppl. 2), 904-904.
Alping, P. , Piehl, F. , Langer-Gould, A. , Frisell, T. , Burman, J. , Fink, K. , Fogdell-Hahn, A. , Gunnarsson, M. & et al. (2019). Validation of the Swedish Multiple Sclerosis Register Further Improving a Resource for Pharmacoepidemiologic Evaluations. Epidemiology, 30 (2), 230-233.
Demirbüker, S. S. , Kågström, S. , Fält, A. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2018). A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5). Multiple Sclerosis, 24 (Suppl. 2), 701-702.
Kågström, S. , Fält, A. , Demirbüker, S. S. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2018). A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1). Multiple Sclerosis, 24 (Suppl. 2), 699-700.
Fält, A. , Kågström, S. , Demirbuker, S. S. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2018). A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3). Multiple Sclerosis, 24 (Suppl. 2), 706-707.
Fält, A. , Kågström, S. , Demirbüker, S. S. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2018). A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2). Multiple Sclerosis, 24 (Suppl. 2), 696-697.
Demirbüker, S. S. , Kågström, S. , Fält, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. , Lycke, J. & et al. (2018). A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4). Multiple Sclerosis, 24 (Suppl. 2), 922-923.
Krauss, W. , Gunnarsson, M. , Nilsson, M. & Thunberg, P. (2018). Conventional and synthetic MRI in multiple sclerosis: a comparative study. European Radiology, 28 (4), 1692-1700.
Biström, M. , Andersen, O. , Alonso-Magdalena, L. , Gunnarsson, M. , Vrethem, M. , Hultdin, J. & Sundström, P. (2018). High serum concentrations of vitamin D may protect against multiple sclerosis. Multiple Sclerosis, 24 (Suppl. 2), 1001-1002.
de Flon, P. , Söderström, L. , Laurell, K. , Dring, A. , Sundström, P. , Gunnarsson, M. & Svenningsson, A. (2018). Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls. PLOS ONE, 13 (2).
Kågström, S. , Fält, A. , Demirbuker, S. S. , Berglund, A. , Hillert, J. , Nilsson, P. , Dahle, C. , Svenningsson, A. & et al. (2018). Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile. Multiple Sclerosis, 24 (Suppl. 2), 927-928.
de Flon, P. , Laurell, K. , Söderström, L. , Gunnarsson, M. & Svenningsson, A. (2017). Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. Multiple Sclerosis, 23 (9), 1249-1257.
Novakova, L. , Zetterberg, H. , Sundström, P. , Axelsson, M. , Khademi, M. , Gunnarsson, M. , Malmeström, C. , Svenningsson, A. & et al. (2017). Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology, 89 (22), 2230-2237.
Novakova, L. , Zetterberg, H. , Axelsson, M. , Sundström, P. , Khademi, M. , Gunnarsson, M. , Malmeström, C. , Svenningsson, A. & et al. (2017). Neurofilament light in serum for monitoring multiple sclerosis: A new quantitative tool for measuring disease activity and therapeutic response. European Journal of Neurology, 24 (Suppl. 1), 577-577.
de Flon, P. , Söderström, L. , Laurell, K. , Gunnarsson, M. & Svenningsson, A. (2016). Changes of cerebrospinal fluid cytokine profile as a result of switching from first line MS-therapies to rituximab. Multiple Sclerosis Journal, 22 (Suppl. 3), 622-622.
Westerdahl, E. , Wittrin, A. , Kånåhols, M. , Gunnarsson, M. & Nilsagård, Y. (2016). Deep breathing exercises with positive expiratory pressure in patients with multiple sclerosis: a randomized controlled trial. Clinical Respiratory Journal, 10 (6), 698-706.
de Flon, P. , Gunnarsson, M. , Laurell, K. , Söderström, L. , Birgander, R. , Lindqvist, T. , Krauss, W. , Dring, A. & et al. (2016). Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology, 87 (2), 141-147.
Nilsagård, Y. , Westerdahl, E. , Wittrin, A. & Gunnarsson, M. (2016). Walking Distance as a Predictor of Falls in People With Multiple Sclerosis. Physiotherapy Research International, 21 (2), 102-108.
Westerdahl, E. , Wittrin, A. , Kånåhols, M. , Gunnarsson, M. & Nilsagård, Y. (2015). Breathing exercises for patients with multiple sclerosis: a randomized controlled trial. Physiotherapy, 101 (Sup. 1).
Gunnarsson, M. , Udumyan, R. , Bahmanyar, S. , Nilsagård, Y. & Montgomery, S. (2015). Characteristics in childhood and adolescence associated with future multiple sclerosis risk in men: cohort study. European Journal of Neurology, 22 (7), 1131-1137.
Burman, J. , Iacobaeus, E. , Svenningsson, A. , Lycke, J. , Gunnarsson, M. , Nilsson, P. , Vrethem, M. , Fredrikson, S. & et al. (2014). Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. Journal of Neurology, Neurosurgery and Psychiatry, 85 (10), 1116-1121.
Westerdahl, E. , Wittrin, A. , Kånåhols, M. , Gunnarsson, M. & Nilsagård, Y. (2014). Breathing exercises for patients with multiple sclerosis: a randomized controlled trial. European Respiratory Journal, 44.
Nilsagård, Y. , Westerdahl, E. , Wittrin, A. & Gunnarsson, M. (2014). Correlation between maximal walking distance and self-rated limitations in walking. Multiple Sclerosis, 20 (7), 992-992.
Axelsson, M. , Malmeström, C. , Gunnarsson, M. , Zetterberg, H. , Sundstrom, P. , Lycke, J. & Svenningsson, A. (2014). Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Multiple Sclerosis, 20 (1), 43-50.
Wittrin, A. , Nilsagård, Y. , Westerdahl, E. & Gunnarsson, M. (2013). Self-assessment of walking ability in patients with multiple sclerosis and its impact on the expanded disability status scale (EDSS) score. Multiple Sclerosis, 19 (11), 118-118.

Articles, reviews/surveys

Conference papers

Westerdahl, E. , Wittrin, A. , Kånåhols, M. , Gunnarsson, M. & Nilsagård, Y. (2015). Breathing exercises for patient with multiple sclerosis. Paper presented at Fysioterapi 2015, Stockholm Waterfront Congress Centre, Stockholm, 21-23 okt, 2015..